Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma

Relapsed refractory primary central nervous system lymphoma (R/R PCNSL) has no recognized optimal therapy due to its grave prognosis and high mortality. This report describes a 69-year-old patient with primary central nervous system lymphoma (PCNSL) who rapidly relapsed after achieving complete remission (CR) on first-line treatment and subsequently received treatment with glofitamab to achieve CR again. Grade 1 cytokine release syndrome was observed and there were no fatal side effects. However, limited reports on glofitamab therapy are applied for relapsed and refractory PCNSL. Further ex vivo data demonstrated that glofitamab drove T cell activation and killing ability against lymphoma cells. Our study suggested that glofitamab may be a viable option for relapsed PCNSL patients.